Lanicemine dihydrochloride |
| Katalog-Nr.GC61842 |
Lanicemin (AZD6765)-Dihydrochlorid ist ein NMDA-Kanalblocker mit geringem Trapping (Ki von 0,56-2,1 μM fÜr den NMDA-Rezeptor; IC50-Werte von 4-7 μM und 6,4 μM in CHO- bzw. Xenopus-Eizellen).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 153322-06-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lanicemine (AZD6765) dihydrochloride is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 µM for NMDA receptor; IC50s of 4-7 µM and 6.4 µM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects[1].
Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects[1].Lanicemine (3, 10 or 30 mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also influences these networks independent of the broader systems-level disruptions typical of ketamine[1].
References:
[1]. Sanacora G, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacywith minimal psychotomimetic adverse effects. Mol Psychiatry. 2014 Sep;19(9):978-85.
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *